Announcement
A trial to test an experimental drug in patients with head and neck cancer launches in the UK today (Friday), through the Combinations Alliance – a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network.
The winners of the 2017 Greater Manchester Clinical Research Awards were revealed during an evening of celebration on Thursday 9 November. Staff from across the region’s Trusts and GP practices gathered in Manchester city centre for the fifth-annual ceremony to toast excellence in health research delivery. Individuals and teams were rewarded for their efforts across 10 categories, while special awards were also presented to an extra four outstanding recipients.
The Molto study has opened at the Christie Hospital, Manchester. The trial is recruiting women with a germline BRCA1/2 mutation and recurrent, platinum-sensitive, high-grade serous or endometrioid ovarian cancer.
The Cardiff ECMC has helped in bringing together expertise from two Welsh hospitals to deliver a new cancer treatment as part of a clinical trial.
For the first time, the Clinical Research Facility (CRF) at the University Hospital of Wales (UHW), Velindre Cancer Centre’s Clinical Trials Unit (CTU) and TC BioPharm Ltd. have joined forces to deliver a study looking into an immunotherapy treatment in patients with advanced cancers.
The ECMC Combinations Alliance and the NIHR CRN Industry Alliance are collaborating to support access to multiple molecules from several of our partners. We invite researchers, from both the ECMC and NIHR networks, to submit novel proposals involving one or more of the novel agents tabled below in combination with standard of care chemotherapy, and/or radiotherapy, and/or another novel drug.
The ECMC Research Nurse Steering Committee met in September to discuss the group's activities for the coming year.
Do you have an interest and passion in translational science applied within ECMC network cancer clinical trials? If so, the Quality Assurance and Translational Science Group (QATS) Network group needs you.
Hear about the challenges and successes of the ongoing TORCMEK trial from Professors Peter Schmid and Gary Middleton from the study team
Since the end of March 2017, 7 patients have been recruited into the Phase I study sponsored by ADC Therapeutics (Lausanne, Switzerland) of a novel antibody drug conjugate ADCT-402 in patients with relapsed/refractory non-Hodgkin lymphoma.
Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet recently. The Cancer Research UK-funded IMPORT LOW trial revealed that five years after treatment, almost all patients were disease free.